DOCSLIB.ORG

Aisys CS² User's Reference Manual Software Revision 10.X User Responsibility

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Aisys CS² User's Reference Manual Software Revision 10.X User Responsibility Aisys CS² User's Reference Manual Software Revision 10.X User responsibility Datex-Ohmeda, Inc. a General Electric Company, doing business as GE Healthcare. This product will perform in conformity with the description thereof contained in this User’s Reference manual and accompanying labels and/or inserts, when assembled, operated, maintained, and repaired in accordance with the instruction provided. This Product must be checked periodically. A defective Product should not be used. Parts that are broken, missing, plainly worn, distorted, or contaminated should be replaced immediately. Should repair or replacement become necessary, Datex-Ohmeda recommends that a telephonic or written request for service advice be made to the nearest Datex- Ohmeda Customer Service Center. This Product or any of its parts should not be repaired other than in accordance with written instructions provided by Datex-Ohmeda and by Datex-Ohmeda trained personnel. The Product must not be altered without the prior written approval of Datex-Ohmeda. The user of this Product shall have the sole responsibility for any malfunction which results from improper use, faulty maintenance, improper repair, damage, or alteration by anyone other than Datex-Ohmeda. CAUTION U.S. Federal law restricts this device to sale by or on the order of a licensed medical practitioner.Outside the U.S.A., check the local laws for any restriction that may apply. Table of Contents 1 Introduction Intended use .....................................1-2 Indications for use ..............................1-2 General information .............................1-2 Serial numbers .................................1-4 Trademarks ...................................1-5 Symbols used in the manual or on the equipment ........1-6 Symbols used on the equipment ...................1-6 Symbols used on the user interface ................1-9 Typeface conventions used ........................ 1-10 Abbreviations ....................................1-11 System information ...............................1-14 System classification ...........................1-14 Device standards IEC 60601-1:2005 .............. 1-14 Device standards IEC 60601-1:1988 .............. 1-14 Integral system components .....................1-15 Not integral system components ..................1-15 System accessories ............................1-15 System safety ................................... 1-16 Preparing for use ..............................1-16 Inspecting the system ..........................1-17 Electrical safety ...............................1-18 2 System controls and menus System overview ..................................2-2 Using the brake ................................2-4 Using the O2 flush button ........................2-4 Positioning the display ...........................2-4 Advanced breathing system components ...............2-6 Using the bag support arm .......................2-7 2067226-001 i Aisys CS² Aladin cassette controls ............................ 2-8 Display controls ...................................2-9 Touch points ................................. 2-10 Measured value touch points .................... 2-10 Active alarm touch points ....................... 2-11 Anesthesia system display .........................2-12 Digit fields ................................... 2-13 Waveform fields ...............................2-13 Split screen field .............................. 2-13 Display navigation ................................2-15 Using menus .................................2-15 Using the ComWheel .......................... 2-16 Using quick keys ..............................2-16 3 Operation System operation safety ............................3-2 Turning on the system ..............................3-3 Start a case ......................................3-4 Minimum Alveolar Concentration .................. 3-4 Starting a case using default settings ...............3-5 Starting a case using custom settings .............. 3-5 End a case ....................................3-6 Turning off the system ..............................3-7 Ventilator setup ...................................3-8 Changing ventilator mode ........................3-8 Changing ventilator settings ......................3-8 Optional ventilator procedures .................... 3-8 Auto limits ....................................... 3-9 Setting auto limits .............................. 3-9 Gas setup ...................................... 3-10 Changing gas settings ..........................3-10 Changing balance gas ..........................3-10 Changing circuit type ...........................3-10 ii 2067226-001 Table of Contents System setup ....................................3-13 Patient demographics ..........................3-13 Screen setup menu ............................3-13 Fresh gas usage ..............................3-16 Alarm setup .....................................3-17 Setting CO2 alarms ............................3-17 Setting MV TV alarms ..........................3-18 Setting alarm limits ............................ 3-18 Viewing alarm history .......................... 3-19 Setting alarm volume ...........................3-19 Setting apnea delay ............................3-19 Silencing leak audio alarms ..................... 3-19 Setting auto MV limits ..........................3-20 Setting to default limits ......................... 3-20 Alarms On Off ...................................3-21 Disable alarm limits ............................3-21 Next page ...................................... 3-22 Trends .........................................3-23 Setting trends ................................ 3-23 Spirometry ......................................3-24 Setting loop type ..............................3-24 Setting loop graph scaling .......................3-25 Setting patient and sensor type ...................3-25 Setting the data source .........................3-25 Setting spirometry volume type ...................3-26 Saving, viewing, and deleting spirometry loops ......3-26 Procedures ..................................... 3-27 Pause gas flow ............................... 3-27 Cardiac bypass ...............................3-27 Vital capacity .................................3-28 Cycling ......................................3-29 Timer function ...................................3-31 Using the timer ............................... 3-31 ecoFLOW .......................................3-32 2067226-001 iii Aisys CS² Using ecoFLOW .............................. 3-33 Alternate O2 control ...............................3-34 Using Alternate O2 control ...................... 3-34 EZchange canister mode .......................... 3-36 Using EZchange canister mode .................. 3-37 Condenser ......................................3-38 Draining the condenser .........................3-38 Auxiliary Common Gas Outlet .......................3-40 Using the ACGO ..............................3-40 4 Preoperative checkout Every day before your first patient .................... 4-2 Before every patient ............................... 4-3 5 Preoperative tests Aladin cassette installation ..........................5-2 Flow and pressure calibration ........................5-3 Circuit compliance compensation .....................5-4 Checkout menu ...................................5-5 Full test ......................................... 5-6 Vent and gas ..................................5-6 Circuit leak ....................................5-6 Circuit O2 cell ................................. 5-7 External gas monitor ............................5-7 Individual tests ....................................5-8 Vent and gas ..................................5-8 Circuit leak ....................................5-8 Circuit O2 cell ................................. 5-8 Low P leak ....................................5-8 Low P leak (machines with ACGO) .................5-9 Agent delivery .................................5-9 Positive low pressure leak test (ACGO systems only) ....5-10 iv 2067226-001 Table of Contents 6 Airway modules Airway modules ...................................6-2 E and M series airway modules ................... 6-3 CARESCAPE airway modules .................... 6-4 Connecting the airway module .......................6-5 Parameters setup ................................. 6-6 Data source ...................................6-6 Automatic agent identification ........................6-7 Calibrating the airway module ........................6-8 7 Alarms and troubleshooting Alarms ..........................................7-2 Alarm priorities .................................7-2 Pausing alarms ................................7-2 Cancelling audio pause ..........................7-3 Display changes during alarms ....................7-3 De-escalating alarms ............................7-3 Battery indicator ................................7-3 Internal failure .................................7-4 Informational tones ............................. 7-4 List of alarms .....................................7-5 Sustained pressure threshold ....................7-12 Alarm ranges ....................................7-13 Alarm tests ......................................7-15 Breathing system problems .........................7-17 Electrical problems ............................... 7-18 Pneumatic problems ..............................7-19 8 Setup and connections Setup safety ......................................8-2 Moving and transporting
Load more

Recommended publications
  • Apch 2017 Delegates' Abstract
    APCH 2017 DELEGATES’ ABSTRACT Topic: Basic Science: Genetics, genomics, proteomics and metabolomics Abstract No: 3630 A PILOT GENOME WIDE ASSOCIATION STUDY (GWAS) IN MULTI ETHNIC POPULATION OF MALAYSIA Ms Syahirah Kaja Mohideen*1 ; Prof Datuk Dr A Rahman A Jamal1 ; Prof Dr Nor Azmi Kamaruddin1 ; Prof Dr Norlela Sukor1 ; Ms Elena Aisha Azizan1 1MEDICINE/ UNIVERSITI KEBANGSAAN MALAYSIA (UKM)/ Malaysia Objective Primary aldosteronism (PA) occurs due to the presence of aldosterone-producing lesions commonly located in the adrenal gland which can thus be cured by an adrenalectomy. Studies on surgically removed tissues found somatic mutations in five genes (KCNJ5, ATP1A1, ATP2B3, CACNA1D, and CTNNB1) can cause the excess aldosterone production. Most of these studies were performed in Caucasian patients. The aim of our study is to understand the genetic background which may promote somatic mutation in these genes and to investigate the frequency and distribution of these somatic mutations in the multiethnic Asian population in Malaysia. Method To characterize the genetic background of PA, a pilot genome wide association study (GWAS) was performed using the Human Infinium OmniExpressExome-8 v1.4 BeadChip containing 960,919 markers to compare gDNA of PA patients with healthy controls. The Association Workflow in Partek® Genomics SuiteTM was used for quality control and association analysis was performed using the Chi-square Test and reported as an odds ratio (OR). On tumour DNA, targeted sequencing of hotspots for the five causal genes were performed. Discussion From the pilot GWAS, two SNPs in chromosome 2 were identified to be associated with PA (OR=11.03, P-value=7.1x10-10, and OR=1.61, P-value=4.0x10-9,).
    [Show full text]
  • In Silico Structure-Function, Specificity and Stability Studies of N-Terminal Nucleophile Hydrolase Enzymes
    IN SILICO STRUCTURE-FUNCTION, SPECIFICITY AND STABILITY STUDIES OF N-TERMINAL NUCLEOPHILE HYDROLASE ENZYMES THESIS SUBMITTED TO SAVITRIBAI PHULE PUNE UNIVERSITY FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN BIOTECHNOLOGY BY PRIYABRATA PANIGRAHI RESEARCH GUIDE Dr. C.G. SURESH DIVISION OF BIOCHEMICAL SCIENCES CSIR-NATIONAL CHEMICAL LABORATORY DR HOMI BHABHA ROAD, PUNE 411008 MAHARASHTRA, INDIA JUNE 2015 DECLARATION BY THE CANDIDATE I hereby declare that the thesis entitled “In silico structure-function, specificity and stability studies of N-terminal nucleophile hydrolase enzymes” submitted by me for the degree of Doctor of Philosophy is the record of work carried out by me during the period from July 2011 to June 2015 under the guidance of Dr. C.G. Suresh, Chief Scientist and has not formed the basis for the award of any degree, diploma, associateship, fellowship, titles in this or any other University or other institution of higher learning. I further declare that the material obtained from other sources has been duly acknowledged in the thesis. Priyabrata Panigrahi Division of Biochemical Sciences CSIR-National Chemical Laboratory Pune - 411 008 June 2015 Acknowledgement This thesis is the end of my journey towards obtaining Ph.D. It would not have been possible to accomplish this without the help, support and encouragement from many people including my well wishers, my friends and colleagues. I would like to express my thanks to everyone who have made this thesis possible and gave me an unforgettable experience. First and foremost, I would like to thank beloved BapDada and Brahmakumaris World Spiritual University for giving me inner strength and willpower to pursue this journey and also their staunch support during tough times.
    [Show full text]
  • Bioinformatic and Biostatitic Analysis of Epigenetic Data from Humans and Mice in the Context of Obesity and Its Complications Sarah Voisin
    Bioinformatic and biostatitic analysis of epigenetic data from humans and mice in the context of obesity and its complications Sarah Voisin To cite this version: Sarah Voisin. Bioinformatic and biostatitic analysis of epigenetic data from humans and mice in the context of obesity and its complications. Development Biology. Université Pierre et Marie Curie - Paris 6; Uppsala University, 2016. English. tel-02800507 HAL Id: tel-02800507 https://hal.inrae.fr/tel-02800507 Submitted on 5 Jun 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1245 Bioinformatic and Biostatistic Analysis of Epigenetic Data from Humans and Mice in the Context of Obesity and its Complications SARAH VOISIN ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6206 UPPSALA ISBN 978-91-554-9655-5 2016 urn:nbn:se:uu:diva-300751 Dissertation presented at Uppsala University to be publicly examined in Uppsala, Thursday, 22 September 2016 at 13:00 for the degree of Doctor of Philosophy (Faculty of Medicine). The examination will be conducted in English. Faculty examiner: Associate professor Romain Barres (Section for Integrative Physiology, University of Copenhagen, Denmark).
    [Show full text]
  • Gene Expression Reprogramming During the Formation of Feeding Sites Induced by Plant Endoparasitic Nematodes
    UNIVERSIDAD DE CASTILLA LA MANCHA FACULTAD DE CIENCIAS AMBIENTALES Y BIOQUÍMICA DEPARTAMENTO DE CIENCIAS AMBIENTALES Gene expression reprogramming during the formation of feeding sites induced by plant endoparasitic nematodes TESIS DOCTORAL JAVIER CABRERA CHAVES (TOLEDO, 2016) UNIVERSIDAD DE CASTILLA LA MANCHA FACULTAD DE CIENCIAS AMBIENTALES Y BIOQUÍMICA DEPARTAMENTO DE CIENCIAS AMBIENTALES ÁREA DE FISIOLOGÍA VEGETAL Gene expression reprogramming during the formation of feeding sites induced by plant endoparasitic nematodes Javier Cabrera Chaves 2016 UNIVERSIDAD DE CASTILLA LA MANCHA FACULTAD DE CIENCIAS AMBIENTALES Y BIOQUÍMICA DEPARTAMENTO DE CIENCIAS AMBIENTALES ÁREA DE FISIOLOGÍA VEGETAL Gene expression reprogramming during the formation of feeding sites induced by plant endoparasitic nematodes Memoria presentada por el licenciado Javier Cabrera Chaves para optar al grado de Doctor por la Universidad de Castilla- La Mancha. Trabajo dirigido por la Dra. Carolina Escobar Lucas de la Universidad de Castilla- La Mancha Toledo, 2016 Vº Bº del Director de Tesis El Doctorando Dra. Carolina Escobar Lucas Javier Cabrera Chaves INDEX INDEX CONCEPTUAL GRAPH SUMMARY CHAPTER 1: Introduction Purpose of the chapter Overview of Root-Knot Nematodes and Giant Cells Developmental Pathways Mediated by Hormones in Nematode Feeding Site The Power of Omics to Identify Plant Susceptibility Factors and to Study Resistance to Root-knot Nematodes AIMS AND OBJECTIVES CHAPTER 2: Holistic analyses on plant- nematode interactions Purpose of the chapter Distinct
    [Show full text]
  • Sessions Posters
    Réanimation (2009) 18S, S48—S187 Sessions posters SP001 Introduction.— La ventilation non invasive (VNI) est devenue une Facteurs prédictifs de succès de la ventilation non thérapeutique majeure de l’insuffisance respiratoire aiguë aux ser- invasive au cours des détresses respiratoires aiguës vices des urgences. L’objectif de notre travail est d’évaluer ce A. Bignon, L. Robriquet, F.Fourrier moyen thérapeutique et de repérer ses meilleures indications dans Service de réanimation polyvalente, CHRU de Lille, hôpital nos conditions de travail. Roger-Salengro, Lille Patients et méthodes.— Notre étude est prospective s’étalant sur une période d’une année (avril 2007—mars 2008) incluant tous les Objectif.— Identifier les facteurs prédictifs du succès de la ventila- patients hospitalisés à l’UHCD des urgences de Sfax et répondant à tion non invasive (VNI). Étude rétrospective et monocentrique. l’un des critères suivants : Matériels et méthodes.— De janvier 2002 à mars 2008, 191 patients — BPCO avec un pH inférieur à 7,35 ; hospitalisés pour détresse respiratoire aiguë dans un service de — OAP avec signes cliniques de détresse respiratoire majeure sans réanimation polyvalente au centre hospitalier régional et univer- chiffres gazométriques ; sitaire de Lille ont bénéficié de séances de VNI. La VNI était —ouPaCO2 > 45 mmHg ; administrée par l’intermédiaire d’une BiPAP vision. Des données cli- — ou non réponse au traitement médical ; niques, gazométriques et les paramètres de ventilation mécanique — immunodéprimé avec rapport PaO2/FiO2 < 200 + infiltrat pulmo- ont été recueillis à l’admission et au cours des 24 premières heures naire ; de traitement. — pneumopathie hypoxémiante avec rapport PaO2/FiO2 < 150. Résultats.— Le taux de succès de la VNI était de 60 %.
    [Show full text]
  • S/5 Aespire User's Reference Manual
    Aespire 7900 User’s Reference Manual—Part 2 Setup, Cleaning and Sterilization, Maintenance and Troubleshooting User Responsibility This Product will perform in conformity with the description thereof contained in this User’s Reference manual and accompanying labels and/or inserts, when assembled, operated, maintained, and repaired in accordance with the instructions provided. This Product must be checked periodically. A defective Product should not be used. Parts that are broken, missing, plainly worn, distorted, or contaminated should be replaced immediately. Should repair or replacement become necessary, Datex-Ohmeda recommends that a telephonic or written request for service advice be made to the nearest Datex-Ohmeda Customer Service Center. This Product or any of its parts should not be repaired other than in accordance with written instructions provided by Datex-Ohmeda and by Datex-Ohmeda trained personnel. The Product must not be altered without the prior written approval of Datex-Ohmeda. The user of this Product shall have the sole responsibility for any malfunction which results from improper use, faulty maintenance, improper repair, damage, or alteration by anyone other than Datex-Ohmeda. w CAUTION U.S. Federal law restricts this device to sale by or on the order of a licensed medical practitioner. Outside the U.S.A., check local laws for any restriction that may apply. Datex-Ohmeda products have unit serial numbers with coded logic which indicates a product group code, the year of manufacture, and a sequential unit number for identification. AAA F 12345 This alpha character indicates the year of product manufacture and when the serial number was assigned; “D” = 2000, “E” = 2001, “F” = 2002, etc.
    [Show full text]
  • Mechanisms of Seizure Propagation in 2-Dimensional Centre-Surround Recurrent Networks
    Mechanisms of Seizure Propagation in 2-Dimensional Centre-Surround Recurrent Networks David Hall1,2, Levin Kuhlmann2* 1 Victoria Research Labs, National ICT Australia, Parkville, Victoria, Australia, 2 Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, Victoria, Australia Abstract Understanding how seizures spread throughout the brain is an important problem in the treatment of epilepsy, especially for implantable devices that aim to avert focal seizures before they spread to, and overwhelm, the rest of the brain. This paper presents an analysis of the speed of propagation in a computational model of seizure-like activity in a 2-dimensional recurrent network of integrate-and-fire neurons containing both excitatory and inhibitory populations and having a difference of Gaussians connectivity structure, an approximation to that observed in cerebral cortex. In the same computational model network, alternative mechanisms are explored in order to simulate the range of seizure-like activity propagation speeds (0.1–100 mm/s) observed in two animal-slice-based models of epilepsy: (1) low extracellular ½Mg2z, which creates excess excitation and (2) introduction of gamma-aminobutyric acid (GABA) antagonists, which reduce inhibition. Moreover, two alternative connection topologies are considered: excitation broader than inhibition, and inhibition broader than excitation. It was found that the empirically observed range of propagation velocities can be obtained for both connection topologies. For the case of the GABA antagonist model simulation, consistent with other studies, it was found that there is an effective threshold in the degree of inhibition below which waves begin to propagate. For the case of the low extracellular ½Mg2z model simulation, it was found that activity-dependent reductions in inhibition provide a potential explanation for the emergence of slowly propagating waves.
    [Show full text]
  • Effect of Lifestyle Intervention Holistic Approach on Blood Glucose Levels
    Acta Scientiarum http://periodicos.uem.br/ojs/acta ISSN on-line: 1807-8648 Doi: 10.4025/actascihealthsci.v43i1.53729 MEDICINA / MEDICINE Effect of lifestyle intervention holistic approach on blood glucose levels, health-related quality of life and medical treatment cost in type 2 diabetes mellitus patients Girija Kumari1*, Vikram Singh2, Bimal Chhajer3 and Ashok Kumar Jhingan4 1Department of Clinical Research, Amity Medical School, Amity University Haryana, Gurgaon, Haryana, 122 413, India. 2Department of Medical Laboratory Technology, Amity Medical School, Amity University Haryana, Gurgaon, Haryana, India. 3Department of Preventive Cardiology, SAAOL Heart Center, Chhatarpur, New Delhi, India. 4Department of Medicine, Delhi Diabetes Research Center, Rajouri Garden, New Delhi, India. *Author for correspondence. E-mail: [email protected] ABSTRACT. Type 2 Diabetes Mellitus (T2DM) is a costly, lifestyle-related disorder, its management is very critical and challenging hence lifestyle intervention may a cornerstone in the reversal and management of T2DM. This study designed to assess the impact of lifestyle intervention holistic (LIH) Model on blood glucose levels (BGL), Health-Related Quality of Life (HRQOL), and medical treatment cost in T2DM patients. This prospective, quasi-experimental study was conducted among 224 T2DM patients in Delhi Diabetes Research Center (DDRC), New Delhi. The study participants were allocated into two groups-Lifestyle Intervention Counseling (LIC) group received lifestyle-based counseling through the LIH model while the Usual-care group received only standard treatment. Study outcomes were assessed at baseline, 3rd, 6th, and 12th month and data were analyzed through SPSS. Study results revealed that LIC participants had decreased in fasting blood glucose 0.26 mg dL-1 (-4.37 to 4.89), blood glucose postprandial -70.16 mg dL-1 (-85.15 to - 55.16), HbA1C -2.82% (-5.26 to - 0.37), medicine cost (p < 0.004), hospitalization cost (p < 0.011), and cost of surgery (p < 0.0005).
    [Show full text]
  • WO 2014/153651 A9 2 October 2014 (02.10.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2014/153651 A9 2 October 2014 (02.10.2014) P O P C T (51) International Patent Classification: 2038 Waycross Crescent, Mississauga, Ontario L5K 1H9 C12Q 1/02 (2006.01) G01N 33/48 (2006.01) (CA). DA COSTA, Daniel J.; 3844 West 11th, Van C12M 1/34 (2006.01) G01N 33/567 (2006.01) couver, British Columbia V6R 2K8 (CA). HANSEN, C12Q 1/68 (2006.01) Carl, L., G.; 6309 Larkin Drive, Vancouver, British Columbia V6T 1Z4 (CA). NELSON, Brad; 312-225 Men- (21) International Application Number: zies Street, Victoria, British Columbia (CA). NIELSEN, PCT/CA20 14/000304 Julie; 2410 Lee Avenue, Victoria, British Columbia V8R (22) International Filing Date: 6V5 (CA). LISAINGO, Kathleen; #402-1 10 Brew Street, 28 March 2014 (28.03.2014) Port Moody, British Columbia V3H 0E4 (CA). (25) Filing Language: English (74) Agent: MACINS, Andris; c/o C6 Patent Group Inc., oper ating as Carbon Patent Group, Unit 203A-1 16 Geary Aven English (26) Publication Language: ue, Toronto, Ontario M6H 4H1 (CA). (30) Priority Data: (81) Designated States (unless otherwise indicated, for every 61/806,329 28 March 2013 (28.03.2013) US kind of national protection available): AE, AG, AL, AM, (71) Applicant: THE UNIVERSITY OF BRITISH AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, COLUMBIA [—/CA]; University - Industry Liaison O f BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, fice, # 103 - 6190 Agronomy Road, Vancouver, BC V6T DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 1Z4 (CA).
    [Show full text]
  • Understanding the Ecology and Epidemiology of Pythium Violae to Enable Disease Management in Carrot Crops Kathryn R
    BSPP & BSM Fungal Control & Exploitation University of Nottingham 11-13 September 2017 Contents Page 2………………………………………………..President’s welcome 4………………………………………………..Programme 10………………………………………………..Awards 12…………………………………………….. Opening plenary talk abstracts 15…………………………………………….. BMS talk abstracts – Exploitation 1 (Tuesday 12th) 19……………………………………………...BMS talk abstracts – Control 1 (Tuesday 12th) 23………………………………………………BMS talk abstracts – Exploitation 2 (Wednesday 13th) 26………………………………………………BMS talk abstracts – Control 2 (Wednesday 13th) 28………………………………………………BSPP talk abstracts (Tuesday 12th) 38………………………………………………BSPP talk abstracts (Wednesday 13th) 44………………………………………………Closing plenary talk abstracts 46………………………………………………Poster abstracts 82………………………………………………Date of next BSPP presidential meeting 1 British Mycological Society and British Society for Plant Pathology Joint Presidential Meeting 2017 Fungal Exploitation and Fungal Control University of Nottingham 11th–13th September 2017 Presidents’ Welcome On behalf of the British Society for Plant Pathology and the British Mycological Society, it is our pleasure to welcome you to this joint annual meeting in Nottingham University. Despite the fact that the two societies share a long history and have much in common, as far as the Organising Committee is aware, this is the first time a joint meeting has been held. The themes of this conference are the control of plant pathogens (mainly fungi) and the exploitation of fungal species. Plant pathogens continue to cause substantial losses to farmers in all parts of the world. The main methods used to control diseases are genetic disease resistance in crop cultivars, fungicides, biological control agents and cultural practices. This conference will highlight significant advances in the first two methods. Cultivars with improved disease resistance, which combines effectiveness with longevity, are being released through partnerships between academic scientists and plant breeding entities.
    [Show full text]
  • Surface Modifications of Nanoparticles for Stability in Biological Fluids
    materials Review Surface Modifications of Nanoparticles for Stability in Biological Fluids Luca Guerrini 1, Ramon A. Alvarez-Puebla 1,2,* and Nicolas Pazos-Perez 1,* ID 1 Departamento de Quimica Fisica e Inorganica and EMaS, Universitat Rovira i Virgili Carrer de Marcel•lí Domingo s/n, 43007 Tarragona, Spain; [email protected] 2 Institución Catalana de Investigación y Estudios Avanzados, Passeig Lluís Companys 23, 08010 Barcelona, Spain * Correspondence: [email protected] (R.A.A.-P.); [email protected] (N.P.-P.) Received: 13 June 2018; Accepted: 2 July 2018; Published: 6 July 2018 Abstract: Due to the high surface: volume ratio and the extraordinary properties arising from the nanoscale (optical, electric, magnetic, etc.), nanoparticles (NPs) are excellent candidates for multiple applications. In this context, nanoscience is opening a wide range of modern technologies in biological and biomedical fields, among others. However, one of the main drawbacks that still delays its fast evolution and effectiveness is related to the behavior of nanomaterials in the presence of biological fluids. Unfortunately, biological fluids are characterized by high ionic strengths which usually induce NP aggregation. Besides this problem, the high content in biomacromolecules—such as lipids, sugars, nucleic acids and, especially, proteins—also affects NP stability and its viability for some applications due to, for example, the formation of the protein corona around the NPs. Here, we will review the most common strategies to achieve stable NPs dispersions in high ionic strength fluids and, also, antifouling strategies to avoid the protein adsorption. Keywords: nanoparticles; biological fluids; colloidal stability; surface modification; protein corona; antifouling; plasmonics; quantum dots; magnetism 1.
    [Show full text]
  • Chemistry and Pharmacology of GABAB Receptor Ligands
    Provided for non-commercial research and educational use only. Not for reproduction, distribution or commercial use. This chapter was originally published in the book GABAB RECEPTOR PHARMACOLOGY: A TRIBUTE TO NORMAN BOWERY (Volume 58). The copy attached is provided by Elsevier for the author’s benefit and for the benefit of the author’s institution, for non-commercial research, and educational use. This includes without limitation use in instruction at your institution, distribution to specific colleagues, and providing a copy to your institution’s administrator. All other uses, reproduction and distribution, including without limitation commercial reprints, selling or licensing copies or access, or posting on open internet sites, your personal or institution’s website or repository, are prohibited. For exceptions, permission may be sought for such use through Elsevier's permissions site at: http://www.elsevier.com/locate/permissionusematerial From Wolfgang Froestl, Chemistry and Pharmacology of GABAB Receptor Ligands. In: Thomas P. Blackburn and S. J. Enna, editors, GABAB Receptor Pharmacology: A Tribute to Norman Bowery (Volume 58). Academic Press, 2010, p. 19. ISBN: 978-0-12-378647-0 © Copyright 2010, Elsevier Inc. Academic Press. Author's personal copy Wolfgang Froestl AC Immune SA, Lausanne, Switzerland Chemistry and Pharmacology of GABAB Receptor Ligands Abstract This chapter presents new clinical applications of the prototypic GABAB receptor agonist baclofen for the treatment of addiction by drugs of abuse, such as alcohol, cocaine, nicotine, morphine, and heroin, a novel baclofen prodrug Arbaclofen placarbil, the GABAB receptor agonist AZD3355 (Lesogabaran) currently in Phase 2 clinical trials for the treatment of gastro­ esophageal reflux disease, and four positive allosteric modulators of GABAB receptors (CGP7930, GS39783, NVP-BHF177, and BHFF), which have less propensity for the development of tolerance due to receptor desensitization than classical GABAB receptor agonists.
    [Show full text]